• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hemostemix Inc (TSV: HEM )

0.0850 UNCHANGED
Streaming Delayed Price Updated: 2:01 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0850
Bid (Size) 0.0800 (80)
Ask (Size) 0.1000 (150)
Prev. Close 0.0850
Today's Range 0.0850 - 0.0850
52wk Range 0.0350 - 0.1100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
September 27, 2022
Calgary, Alberta--(Newsfile Corp. - September 27, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")... 
Via Newsfile
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
September 20, 2022
Calgary, Alberta--(Newsfile Corp. - September 20, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")... 
Via Newsfile

Performance

YTD
+21.43%
+21.43%
1 Month
+30.77%
+30.77%
3 Month
+88.89%
+88.89%
6 Month
+112.50%
+112.50%
1 Year
+16.44%
+16.44%

More News

Read More
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
September 16, 2022
Via Newsfile
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
September 15, 2022
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board
September 14, 2022
Via Newsfile
Hemostemix Announces Its Presentation to the Emerging Growth Conference
September 14, 2022
Via Newsfile
Topics Economy Intellectual Property
Exposures COVID-19 Economy Intellectual Property
Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
September 13, 2022
Via Newsfile
Hemostemix Announces Closing of $2,750,000
April 26, 2022
Via IssueWire
Topics Intellectual Property
Exposures Intellectual Property
Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed
April 13, 2022
Via IssueWire
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years
September 14, 2021
Via Newsfile
Topics Economy Intellectual Property
Exposures COVID-19 Economy Intellectual Property
Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results
July 06, 2021
Via Newsfile
Topics Economy Intellectual Property
Exposures COVID-19 Economy Intellectual Property
Peter Lacey Increases His Investment in Hemostemix Inc.
June 21, 2021
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
June 11, 2021
Via Newsfile
Topics Economy Intellectual Property
Exposures COVID-19 Economy Intellectual Property
Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record
May 31, 2021
Via Newsfile
Topics Economy Intellectual Property
Exposures COVID-19 Economy Intellectual Property
Hemostemix to Present at the Emerging Growth Conference
May 25, 2021
Via Newsfile
Topics Economy Intellectual Property
Exposures COVID-19 Economy Intellectual Property
CEO Presenting on the Emerging Growth Conference on May 26
May 24, 2021
Via EIN Presswire
Topics Cannabis LGBTQ
Exposures Cannabis Diversity
Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list
April 23, 2021
Via Newsfile
Topics Economy Intellectual Property
Exposures COVID-19 Economy Intellectual Property
Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd.
April 08, 2021
Via Newsfile
Topics Economy Intellectual Property
Exposures COVID-19 Economy Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap